The era of Spinal Cord Stimulation

is yet to come

Conventional epidural SCS lacks effectiveness. Spinally disrupt the status quo in SCS treatment.

SCS for treating chronic pain, first used by Dr. Shealy in the 1960s, has mostly stayed the same over the years. Companies have miniaturized the device, redesigned the electrodes, improved battery life, and modified the stimulation parameters and protocol. Around 2010, one of the key market players developed high-frequency SCS, the first real breakthrough. In recent years, closed-loop solutions, in which stimulation is coupled to data recorded from the patient’s body, have been tested. 

Nevertheless, despite these efforts, these treatments didn’t achieve full efficacy, may come with side effects, and are uncomfortable for patients, leading to less frequent adoption by doctors and patient abandonment of the therapy.

I have been experiencing this pain for 2 years now. It’s so severe that I pray for just a few days without it. If the stimulator doesn’t provide relief, the next options are amputation of my feet or suicide!

Javier H.R., 31 years old
Complex Pain Regional Syndrome

The primary inconvenience of my stimulator is the need to charge it practically every second day. This requires me to remain still, taking me away from my duties for two hours.

Ana G.P., 43 years old
Lower Leg Pain

We have successfully addressed all drawbacks associated with currently used SCS, enhancing efficacy, patient comfort, meeting healthcare system requirements, and aligning with the needs of key industry players. Our invention not only promises sustainable and effective chronic pain treatment but also presents opportunities in neurorehabilitation, neurorestoration, spasticity, Parkinson’s, Refractory Angina Pectoris, and various other neurological disorders.

First intrathecal Spinal Cord Stimulation (iSCS)

We developed the FuturaLead™ – an ultra-thin and technologically advanced spinal cord stimulation lead designed for intrathecal implantation, positioned precisely on the surface of the spinal cord. Our technology offers significant advantage by eliminating any tissue barriers between the electrode and spinal cord and benefits from the conductivity of cerebrospinal fluid.

Spinally is not only about stimulation. Our lead delivers unparalleled quality in neural signal recording, opening the door to personalized therapy. FuturaLead™ can measure, among other parameters, the Evoked Compound Action Potentials (ECAPs), which stands as the sole viable stance to enhance treatment efficiency through a closed-loop approach.

Conventional Spinal Cord Stimulation

Standard electrodes are implanted epidurally, meaning they are placed outside the dura mater. This requires the electric current to pass through several layers of tissue, before reaching the spinal cord. As a result, about 90% of the energy is lost or dispersed along this path. Existing spinal cord stimulation devices consuming a significant amount of energy while having limited capacity to deliver it effectively. Consequently, stimulation only reaches the superficial layer of the posterior columns, without affecting deeper axons, which greatly hampers efficacy.

The market

Chronic pain ranks among the primary contributors to disability and the overall burden of disease worldwide. It impacts every aspect of life, not only health, and not only the patient themselves but also those around them. As a result, it has a dramatic effect on quality of life, as well as incurring significant financial costs.

80 M patients in the US and EU alone

$635 Bn spendings in the US alone in 2010

$145 Bn valuation of Chronic Pain Treatment Market in 2030

7.1% Compound Annual Growth Rate 2020-2030

Opioid Epidemia

Between 1999 and 2021, opioids claimed the lives of 645,000 people, a staggering toll akin to wiping out the entire populations of Washington or Copenhagen. The CDC reports that the number of drug overdose deaths in 2021 was over six times higher than in 1999. There was a more than 16% increase in drug overdose deaths from 2020 to 2021, resulting in the nearly 100,000 opioid overdose deaths in 2021 alone. This number continues to rise.

Carles García-Vitoria

Anesthesiologist with an entrepreneurial profile. Interventional pain physician, executive MBA and former inventor of medical devices. ESRA research grant awardee, Instituto de Salud Carlos III researcher.

Pawel Soluch

21 years involved in diagnostic and therapy technologies for neuro & psychiatry. Award-winning inventor and entrepreneur. Seasoned CEO, commercialized medical devices and lab equipments.

Beatriz Llamusí

CSO and Co-founder of Arthex Biotech. PhD studies focused on spinal cord regeneration therapies. Principal investigator +10 years in the University of Valencia. Author of more than 30 scientific articles, and inventor of 7 patents.

Andrés E. Izquierdo

Economist and financial strategy leader, former 2x startup founder. Part of the M&A Transactions Services at Deloitte. Under the Chartered Financial Analyst programme by CFA Institute.

Richard Nash

17 years experience in the MedTech industry, Richard has held corporate positions in BD, strategy and leadership at Medtronic. More recently a CEO & advisor of global MedTech start-ups, with a focus on neuromodulation.

Guillermo V. Carbajal

Neuroscientist specialized in electrophysiology, neuromodulation & data analytics. 7 years of research with animal models & human using extracellular recordings, evoked potentials, EEG and MEG. 10 scientific articles.

Prof. Eric Grigsby

Global Key Opinion Leader. 40 years in the Pain Management. Founder of Napa Pain Institute. CMO at Alfred Mann Foundation ($8B of medical devices exits). Actively engaged in research, clinical practice and education in the field of pain management.

Prof. David Abejon

Key Opinion Leader in neuromodulation. Internationally recognized for publications and contributions to the field. Founder and President of several international societies for pain treatment. Director of several specialized medical teams for pain management.

Prof. Nacho Redondo García

Senior Lecturer and Head of Service of Veterinary Anesthesiology of Universidad Cardenal Herrera. Experienced researcher in clinical trials, including spinal cord space. Founder and Member of several international societies. Author of over 100 papers and 180 presentations.

GENESIS Tech Transfer Boost invested in Spinally.

Josep Lluís Falcó, Genesis Biomed CEO: No doubt, Spinally is poised to revolutionize chronic pain therapy, as their intrathecal lead addresses disadvantages of current solutions. We’ve had pleasure of working with Spinally team for almost a year, during which they’ve demonstrated extensive knowledge about neurotechnology, regulatory and commercialization. Moreover, Carles Garcia-Vitoria’s experience in pain therapy adds value at every step of their development. Press release.

Want to know more?

If you’re interested in learning more about our technology or joining us in our mission, or if you’re considering investment opportunities, please feel free to contact us.

Our technology has not yet been approved for commercial use.